Seeking Alpha

XOMA +4% as gevokizumab wins FDA orphan drug status

  • XOMA Corp. (XOMA +4%) hits a new 52-week high after confirming late yesterday that the FDA granted orphan drug status for its gevokizumab antibody as a treatment for the treatment of pyoderma gangrenosum, a condition which causes skin tissue to develop deep uclers.
  • Gevokizumab is now in Phase III testing to measure its ability to treat acute, non-infectious inflammation of the iris and other vascular structures of the eye in patients with Behcet's uvelitis.
Comments (3)
  • Stephen Tips
    , contributor
    Comments (283) | Send Message
    Over 68% owned by institutional holders. 20 million + shares owned by Baker Brothers, I have been patient and long for some time and it looks like this will be the start of something big.


    Hopefully, this means many will receive better treatment in the future.
    25 Feb, 03:39 PM Reply Like
  • panchosfc
    , contributor
    Comments (37) | Send Message
    and a partnership with Novartis too !!!
    25 Feb, 08:32 PM Reply Like
  • Rootarmo
    , contributor
    Comments (216) | Send Message
    Not only that but Baker Brothers have a seat on the board. I did nothing more then just follow their actions on this one, bet big with it. I am glad I did.
    26 Feb, 09:22 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: